Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT02673138
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 45 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will be an open-label, cross-over study as subjects will be studied under both study conditions - suspension of subcutaneous insulin infusion via pump during treatment with insulin alone (control) vs. suspension of subcutaneous insulin via pump during treatment with insulin and canagliflozin.

Key Dates

Start date
Jan 31, 2016
Status verified
Sep 2021
Primary completion
Jan 31, 2017
Completion
Jul 31, 2017

Study Design

Enrollment
10 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Active Comparator: Basal interruption
    Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit
  • Experimental: Basal interruption with canagliflozin
    Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit

Primary Outcome Measure

Differences in Plasma Glucose Levels Following the Interruption of Basal Subcutaneous Infusion of Insulin [ Time Frame: 20 hours ]

Locations (1)

FacilityCityStateZIPSite coordinators
Yale University School of MedicineNew HavenConnecticut06520-

Find similar trials in New Haven, CT

By condition
Type 1 diabetes
By specialty
Endocrinology
By research site
Yale University School of Medicine· New Haven, CT

Related Studies